

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of groups n = 5

Dead line: 08.05.2018

## EQA round: E12/18 - Hormones 1

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability										Traceability												
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>		
<b>(121) Total T3</b>					1								1	1	100%							1	1	100%
Samples and groups	[nmol/L]																							
<b>Sample A</b>		2,46			1								1	1	100%	CRV	2,897	0,029	20%	2,31	3,48	1	1	100%
Other					1	0							1										1	
						1x 4/29										1x 4/29								
<b>Sample B</b>		5,90			1								1	1	100%	CRV	5,995	0,079	20%	4,79	7,2	1	1	100%
Other					1	0							1										1	
						1x 4/29										1x 4/29								
<b>(122) Total T4</b>					1								1	1	100%							1	0	0,00
Samples and groups	[nmol/L]																							
<b>Sample A</b>		85,8			1								1	1	100%	CRV	103,7	1,0	17%	86	122	1	0	0,00
Other					1	0							1										1	
						1x 4/29										1x 4/29								
<b>Sample B</b>		160			1								1	1	100%	CRV	174,8	2,1	17%	145	205	1	1	100%
Other					1	0							1										1	
						1x 4/29										1x 4/29								
<b>(123) TSH</b>					22								22	22	100%							0		
Samples and groups	[mU/L]																							
<b>Sample A</b>		15,7	1,3	8,0	22								22	22	100%							0		
(4) LIA (CLIA, CMIA, ILMA); (12)		14,2	0,57	4,0	6	0	CVPG	14,2	0,13	14%	12,2	16,2	6											
Beckman Coulter																								
(4) LIA (CLIA, CMIA, ILMA); (60)		16,5	0,47	2,9	12	0	CVPG	16,7	0,050	14%	14,3	19,1	12											
Roche																								
Other					4	0							4											
						1x 3/25, 1x 4/29, 2x 4/179																		
<b>Sample B</b>		19,8	1,6	8,1	22								22	22	100%							0		
(4) LIA (CLIA, CMIA, ILMA); (12)		17,8	1,6	9,2	6	0	CVPG	17,7	0,17	14%	15,2	20,2	6											
Beckman Coulter																								
(4) LIA (CLIA, CMIA, ILMA); (60)		20,9	0,61	2,9	12	0	CVPG	21	0,067	14%	18	24	12											
Roche																								
Other					4	0							4											
						1x 3/25, 1x 4/29, 2x 4/179																		
<b>(124) Free T4</b>					21								21	17	81%							0		
Samples and groups	[pmol/L]																							
<b>Sample A</b>		19,0	2,8	15	21								21	17	81%							0		
(4) LIA (CLIA, CMIA, ILMA); (12)		15,4	0,36	2,4	5	0	CVPG	15,4	0,19	13%	13,3	17,5	5											
Beckman Coulter																								
(4) LIA (CLIA, CMIA, ILMA); (60)		20,7	0,72	3,5	12	0	CVPG	20,4	0,096	13%	17,7	23,1	12											
Roche																								
Other					4	0							4											
						1x 1/36, 1x 3/25, 2x 4/179																		
<b>Sample B</b>		38,9	5,8	15	21								21	18	86%							0		
(4) LIA (CLIA, CMIA, ILMA); (12)		34,8	2,9	8,4	5	0	CVPG	33,3	0,34	13%	28,9	37,7	5											
Beckman Coulter																								



## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of groups n = 5

## EQA round: E12/18 - Hormones 1

Dead line: 08.05.2018

Test	[unit]	Comparability					Traceability																		
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>			
<b>(303) Aldosterone</b>	[nmol/L]				2							2	2	100%									0		
Samples and groups																									
<b>Sample A</b>		0,497	0,02	5,3	2							2	2	100%									0		
Other					2	0						2													
<b>Sample B</b>		1,18	0,00	0,51	2							2	2	100%									0		
Other					2	0						2													
<b>(304) Progesterone</b>	[nmol/L]				14							14	13	93%									0		
Samples and groups																									
<b>Sample A</b>		30,9	7,6	25	14							14	13	93%									0		
(4) LIA (CLIA, CMIA, ILMA); (60)		36,1	1,7	4,7	6	0	CVPG	35	0,28	20%	28	42		6											
Roche																									
Other					8	0								8											
<b>Sample B</b>		38,7	7,8	20	14							14	13	93%									0		
(4) LIA (CLIA, CMIA, ILMA); (60)		43,9	3,4	7,9	6	0	CVPG	43,3	0,33	20%	34,6	52		6											
Roche																									
Other					8	0								8											
<b>(305) Testosterone</b>	[nmol/L]				16							16	14	88%								16	15	94%	
Samples and groups																									
<b>Sample A</b>		25,0	3,1	13	16							16	15	94%	CRV	25,05	0,25	30%	17,5	32,6		16	15	94%	
(4) LIA (CLIA, CMIA, ILMA); (60)		26,4	1,3	5,0	9	0	CVPG	26,2	0,19	22%	20,4	32		9								9			
Roche																									
Other					7	0								7										7	
<b>Sample B</b>		37,5	5,3	14	16							16	14	88%	CRV	37,58	0,38	30%	26,3	48,9		16	15	94%	
(4) LIA (CLIA, CMIA, ILMA); (60)		39,7	2,0	5,0	9	0	CVPG	39,5	0,29	22%	30,8	48,2		9								9			
Roche																									
Other					7	0								7										7	
<b>(306) 17-OH-progesterone</b>	[nmol/L]				2							1	1	100%								2	2	100%	
Samples and groups																									
<b>Sample A</b>		13,3	1,8	13	2							1	1	100%	CRV	12,73	0,13	44%	7,12	18,4		2	2	100%	
Other					2	0								1										2	
<b>Sample B</b>		13,3	2,5	19	2							1	1	100%	CRV	11,91	0,14	44%	6,66	17,2		2	2	100%	
Other					2	0								1										2	
<b>(307) DHEA-S</b>	[µmol/L]				7							7	6	86%										0	
Samples and groups																									
<b>Sample A</b>		19,4	2,2	11	7							7	6	86%										0	
(4) LIA (CLIA, CMIA, ILMA); (60)		19,3	1,5	7,7	5	0	CVPG	18,4	0,26	21%	14,5	22,3		5											
Roche																									
Other					2	0								2											
<b>Sample B</b>		15,4	1,3	8,2	7							7	6	86%										0	
(4) LIA (CLIA, CMIA, ILMA); (60)		15,4	0,85	5,5	5	0	CVPG	14,3	0,20	21%	11,2	17,4		5											
Roche																									
Other					2	0								2											

